PharmaCyte Biotech Inc (PMCB)

[tulla236a]

this is the way i see it.

pmcb can buyout all rights to ciab within a 5 year period. if someone wants buy all rights to ciab, they do it through pmcb. austrianova will get 4% for the mj, diabetes and assets and 50% of all other ciab uses. so each segment of ciab has to have a separate value place on it. so we are gaining 50% of all other uses that we didn't have before, stem cell?

or

pmcb can sublicenses the diabetes, pc, and mj part and austrianova will get 20% of the sublicensees gross sales with the potential to get 50% of their first 2%.

if i am reading this right, we will get more on an all out rights buyout.